These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9143604)

  • 21. HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element.
    Roebuck KA; Rabbi MF; Kagnoff MF
    AIDS; 1997 Feb; 11(2):139-46. PubMed ID: 9030359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.
    Gyetko MR; Shollenberger SB; Sitrin RG
    J Leukoc Biol; 1992 Mar; 51(3):256-63. PubMed ID: 1311745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in tumor angiogenesis associated with stable expression of the HIV tat gene.
    Huber BE; Richards CA; Martin JL; Wirth PJ
    Mol Carcinog; 1992; 5(4):293-300. PubMed ID: 1379815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translational effects of peptide antagonists of Tat protein of human immunodeficiency virus type 1.
    Choudhury I; Wang J; Stein S; Rabson A; Leibowitz MJ
    J Gen Virol; 1999 Mar; 80 ( Pt 3)():777-782. PubMed ID: 10092019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.
    Robinson D; Elliott JF; Chang LJ
    Gene Ther; 1995 Jun; 2(4):269-78. PubMed ID: 7552987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of metastasis by inhibition of the urokinase receptor.
    Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transactivation of heterologous promoters by HIV-1 tat.
    Han P; Brown R; Barsoum J
    Nucleic Acids Res; 1991 Dec; 19(25):7225-9. PubMed ID: 1662814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasminogen activator activity during decidualization of human endometrial stromal cells is regulated by plasminogen activator inhibitor 1.
    Schatz F; Aigner S; Papp C; Toth-Pal E; Hausknecht V; Lockwood CJ
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2504-10. PubMed ID: 7629251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tat-induced lesions in transgenic mice do not correlate with the HIV-1 LTR transactivation.
    Fergelot P; Molina T; Blanchet P; Grimber G; Duquenne O; Couton D; Zider A; Briand P; Cavard C
    C R Acad Sci III; 1995 Mar; 318(3):329-37. PubMed ID: 7788501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein.
    Corallini A; Betti M; Rusnati M; Campioni D; Ciomei M; Sola F; Calza N; Zauli G; Presta M; Barbanti-Brodano G; Caputo A
    AIDS Res Hum Retroviruses; 1998 Nov; 14(17):1561-71. PubMed ID: 9840289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 Tat modulates invasion by a bacterial enteric pathogen into a human intestinal cell line.
    Mayer HB; Wanke CA; Du B; Hammer SM; Terwilliger EF
    AIDS; 1995 Nov; 9(11):1237-42. PubMed ID: 8561976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A high-level expression vector for human cells.
    Subramanian T; Chinnadurai G
    Gene; 1992 Oct; 120(2):287-9. PubMed ID: 1398142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.
    Chen H; He J; Fong S; Wilcox G; Wood C
    J Virol; 2000 Mar; 74(6):2703-13. PubMed ID: 10684286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant.
    Balboni PG; Bozzini R; Zucchini S; Marconi PC; Grossi MP; Caputo A; Manservigi R; Barbanti-Brodano G
    J Med Virol; 1993 Dec; 41(4):289-95. PubMed ID: 8106862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.
    Drysdale CM; Pavlakis GN
    J Virol; 1991 Jun; 65(6):3044-51. PubMed ID: 2033665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element.
    Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN
    Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
    Jiang MC; Lin JK; Chen SS
    Biochem Biophys Res Commun; 1996 Sep; 226(1):1-7. PubMed ID: 8806583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of responsiveness of a nuclear factor-kappaB-regulated promoter to transactivation by human immunodeficiency virus 1 Tat in HeLa cells.
    Kelly GD; Morris CB; Offermann MK
    Virology; 1999 Oct; 263(1):128-38. PubMed ID: 10544088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.